Soumyanarayanan, U;
Ramanujulu, PM;
Mustafa, N;
Haider, S;
Fang Nee, AH;
Tong, JX;
Tan, KSW;
... Dymock, BW; + view all
(2019)
Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
European Journal of Medicinal Chemistry
, 184
, Article 111755. 10.1016/j.ejmech.2019.111755.
Preview |
Text
Shozeb Manuscript_HDAC3-6_EJMC.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Herein, we report the discovery of a dual histone deacetylase inhibitor displaying a unique HDAC3/6 selectivity profile. An initial strategy to merge two epigenetic pharmacophores resulted in the discovery of potent HDAC6 inhibitors with selectivity over HDAC1. Screening in an HDAC panel revealed additional low nanomolar inhibition only against HDAC3. Low micromolar antiproliferative activities against two breast cancer and four hematological cancer cell lines was supported by pharmacodynamic studies on a preferred molecule, 24c, substantiating the HDAC inhibitory profile in cells. Apoptosis was identified as one of the main cell death pathways. Modelling studies of 24c against HDAC1,2,3 and 6 further provided insights on the orientation of specific residues relevant to compound potency, explaining the observed HDAC3/6 selectivity. A subset of the compounds also exhibited good antimalarial activities, particularly against the chloroquine-resistant strain K1 of P.falciparum. In vitro studies revealed a favourable DMPK profile warranting further investigation of the therapeutic potential of these compounds.
Archive Staff Only
 |
View Item |
